Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon to Provide Metabolomic Profiling Services to GSK

NEW YORK (GenomeWeb) – Metabolon today announced a collaboration to provide metabolomic profiling services to GlaxoSmithKline.

The two firms also will collaborate on research projects using Metabolon's DiscoveryHD4 platform. Financial and other terms of the agreement were not disclosed.

GSK will have access to Metabolon's bioinformatics tools, proprietary disease ontologies, and visualization tools to integrate metabolomics data with existing genomics and proteomics data, Metabolon said.

"We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic 'picture' with the aim of yielding translatable, meaningful results," Metabolon President and CEO John Ryals said in a statement. "Gaps of knowledge can be bridged through the understanding [that] metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic, and reduced risk and cost."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.